Effect of vildagliptin on glucagon concentration during meals in patients with type 1 diabetes.
Foley
J E
JE
Novartis Pharmaceutical Corporation, One Health Plaza, East Hanover, NJ 07936, USA. james.foley@novartis.com
Ligueros-Saylan
M
M
He
Y-L
YL
Holst
J J
JJ
Deacon
C F
CF
Dunning
B E
BE
Leone-Jones
A
A
Yu
T
T
Kelley
D E
DE
D000218:Adamantane / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D000328:Adult; D003922:Diabetes Mellitus, Type 1 / Q000097:blood* / Q000188:drug therapy*; D005247:Feeding Behavior / Q000187:drug effects; D005260:Female; D005749:Gastric Inhibitory Polypeptide / Q000097:blood; D005934:Glucagon / Q000097:blood*; D052216:Glucagon-Like Peptide 1 / Q000097:blood; D006801:Humans; D007003:Hypoglycemia / Q000188:drug therapy; D007004:Hypoglycemic Agents / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D008297:Male; D009570:Nitriles / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D011759:Pyrrolidines / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D000077597:Vildagliptin
D007004:Hypoglycemic Agents; D009570:Nitriles; D011759:Pyrrolidines; D005749:Gastric Inhibitory Polypeptide; D052216:Glucagon-Like Peptide 1; D005934:Glucagon; D000077597:Vildagliptin; D000218:Adamantane